Top Page
Ascletis Pharma, Inc.
(1672)
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Ascletis Pharma, Inc. Business Overview & Revenue Model
Ascletis Pharma, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36M | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 856.00K | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -408.21M | -390.45M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -258.57M | -300.94M | -144.72M | -314.84M | -199.02M | -209.24M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 4.27M | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 129.00M | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.87B | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | ||||||
| Free Cash Flow | -313.25M | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -311.15M | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 1.62B | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -72.54M | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Ascletis Pharma, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$38.94B | 43.75 | 27.37% | ― | 2.57% | 18.79% | |
| ― | HK$9.98B | ― | -42.46% | ― | 1219.19% | 25.15% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$9.11B | -32.00 | -12.74% | ― | -76.58% | -4.90% | |
| ― | HK$3.34B | ― | -129.05% | ― | ― | -18.99% | |
| ― | HK$11.52B | -55.06 | -21.42% | ― | 240.05% | -140.09% |
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma Inc. has completed enrollment for a U.S. Phase IIa study of its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30, aimed at treating obesity. This milestone marks significant progress in the development of ASC30, which has demonstrated a 46-day half-life, supporting its potential as a once-monthly treatment option. Topline data from this study are expected in the first quarter of 2026, potentially impacting the company’s market positioning in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has completed a pre-New Drug Application consultation with the China National Medical Products Administration for its drug denifanstat (ASC40), aimed at treating moderate-to-severe acne vulgaris. The drug has shown significant efficacy and a favorable safety profile in Phase III trials, with no severe adverse events reported. Ascletis plans to submit an NDA soon, which could enhance its market position in dermatological treatments in Greater China.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the selection of ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, for clinical development. ASC35 has shown promising results in preclinical studies, demonstrating a longer half-life and greater efficacy in weight reduction compared to tirzepatide, positioning it as a potentially best-in-class treatment for obesity. The company plans to submit an Investigational New Drug Application for ASC35 to the FDA by the second quarter of 2026, which could significantly impact its market positioning and offer scalability advantages in manufacturing.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced its intention to repurchase up to 96,284,628 shares, equivalent to 10% of its issued shares, under a repurchase mandate approved by shareholders. The company plans to use up to HK$300 million of its internal financial resources for this initiative, aiming to enhance shareholder value and reflect confidence in its long-term business prospects. The repurchase will be conducted in compliance with relevant regulations and will not adversely impact the company’s financial position.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the grant of 650,000 share options to 10 employee participants under its 2025 Share Option Scheme. This move is part of the company’s strategy to incentivize its workforce, with options exercisable over a period of five years starting from 2026. The grant aims to align employee interests with company performance, although no specific performance targets are required for the options to vest. The announcement reflects Ascletis Pharma’s commitment to employee engagement and retention, potentially strengthening its position in the competitive pharmaceutical industry.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that its weight loss drug candidate, ASC47, in combination with semaglutide, showed a significant reduction in body weight in obese participants compared to semaglutide alone. The study demonstrated better gastrointestinal tolerability and a lower rebound effect after treatment discontinuation, suggesting ASC47’s potential as a maintenance therapy. These findings could enhance Ascletis’s positioning in the weight management sector, offering a promising option for obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced the successful results of its Phase III clinical trial for Denifanstat (ASC40), a first-in-class FASN inhibitor for the treatment of moderate to severe acne vulgaris. The trial met all primary and secondary efficacy endpoints, demonstrating significant improvements in acne symptoms compared to placebo, with a favorable safety profile. The company is in the process of consulting with the China National Medical Products Administration (NMPA) for a New Drug Application (NDA), which could enhance its market positioning in dermatology and potentially benefit stakeholders by expanding its product portfolio.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising results from its Phase Ib study of ASC30, an oral GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting. The study demonstrated significant weight reduction in participants with obesity and confirmed the drug’s safety and tolerability, with only mild to moderate gastrointestinal side effects. This development highlights Ascletis’ potential to impact the obesity treatment market positively and underscores its commitment to advancing effective therapeutic solutions.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced a voluntary lock-up undertaking by its controlling shareholders, Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, who have committed not to dispose of their shares until the completion of key clinical studies. This move reflects their confidence in the company’s long-term prospects and aims to reassure investors about the company’s future developments in obesity treatment. The lock-up involves 575,952,078 shares, representing approximately 58.03% of the company’s total shares, and is linked to the outcomes of clinical trials expected by the end of 2025.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the successful demonstration of an ultra-long-acting subcutaneous depot maintenance formulation of its small molecule GLP-1 receptor agonist, ASC30, which showed a 75-day observed half-life in a U.S. Phase Ib study involving participants with obesity. This advancement supports once-quarterly administration, addressing a significant unmet need for maintenance therapy in chronic weight management. The formulation demonstrated favorable tolerability with minimal gastrointestinal side effects, potentially enhancing patient compliance and quality of life.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that it will present the results of its 28-day multiple ascending dose study of ASC30, an oral small molecule GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting in Vienna. The study demonstrated superior weight loss in participants with obesity, positioning ASC30 as a potentially differentiated treatment option. The company is on track to report topline data from a Phase IIa clinical study in the fourth quarter of 2025, which could enhance its market position in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising results from its U.S. Phase Ib study of the ASC30 oral once-daily tablet, which showed significantly higher drug exposure compared to orforglipron, a competing treatment. This higher exposure is linked to greater weight loss in participants with obesity, positioning ASC30 as a potentially competitive treatment. The study also highlighted ASC30’s favorable safety and tolerability profile, with no serious adverse events reported, suggesting its potential as a differentiated option in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma, Inc. announced the completion of a placing and subscription of shares, raising approximately HK$467.69 million in net proceeds. The funds are primarily earmarked for advancing the company’s drug candidates into clinical trials for obesity, with a small portion allocated for general corporate purposes. This strategic move is expected to bolster Ascletis Pharma’s R&D capabilities and strengthen its market position.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.75 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma, Inc. announced a placing and top-up subscription agreement involving the sale of 52,400,000 existing shares and the issuance of 28,820,000 new shares. The transaction is expected to raise approximately HK$467.69 million in net proceeds, which will be primarily used for advancing clinical trials for obesity treatments and general corporate purposes. This strategic move is aimed at strengthening the company’s financial position and supporting its R&D initiatives, although it will result in a slight reduction of the controlling shareholders’ stake in the company.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising preclinical results for its obesity treatment drug candidates, ASC47 and ASC31, demonstrating significant weight loss in an animal model. The combination of these drugs showed a 44.8% reduction in body weight, outperforming a similar combination with tirzepatide, indicating potential differentiation in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced its unaudited interim results for the six months ending June 30, 2025, highlighting a significant reduction in losses by 32.5% compared to the previous year, despite increased R&D costs. The company made notable progress in its metabolic disease pipeline, including advancements in obesity and acne treatments, underscoring its strong R&D capabilities and commitment to addressing unmet clinical needs. Ascletis has sufficient cash reserves to support its operations and research activities until 2029.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising preclinical results for its muscle-preserving weight loss drug candidate, ASC47, when combined with tirzepatide. In a study involving diet-induced obese mice, the combination demonstrated an 87% greater reduction in body weight compared to tirzepatide monotherapy, and significantly outperformed the combination with semaglutide. These findings suggest that ASC47, when used with tirzepatide, could potentially offer a more effective treatment for obesity, enhancing Ascletis’s position in the pharmaceutical industry and providing promising implications for stakeholders interested in obesity treatments.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has completed enrollment for its U.S. Phase IIa study of ASC30, a small molecule oral GLP-1R agonist designed for obesity treatment. This milestone highlights the rapid enrollment of 125 participants, indicating a significant unmet need for obesity treatments. The study aims to evaluate the efficacy, safety, and tolerability of ASC30, with topline data expected in the fourth quarter of 2025. ASC30, developed in-house, offers potential once-daily oral and once-monthly subcutaneous dosing options, which could enhance the company’s positioning in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the dosing of the first participants in its U.S. Phase IIa study of ASC30, a once-monthly subcutaneous depot formulation of a small molecule GLP-1 receptor agonist, for the treatment of obesity. The study aims to evaluate the safety, tolerability, and efficacy of ASC30, which has demonstrated a 36-day half-life, supporting its monthly administration. This development positions Ascletis as a competitive player in the obesity treatment market, with ASC30 being the only once-a-month incretin with a half-life greater than the intended dosing interval, potentially offering better tolerability compared to existing treatments.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.